Medulloblastoma

Medulloblastoma is a highly aggressive neuroectodermal tumor that occurs primarily in the cerebellum. It accounts for approximately 20% of all primary brain tumors in children and is usually diagnosed in children between the ages of 3 and 8. However, medulloblastoma can also occur in adults, although this is much less common. The tumor is characterized by rapid growth and the ability to metastasize to the spinal cord and other parts of the central nervous system, making it potentially dangerous. Medulloblastomas are classified based on molecular subtypes, which have different prognoses and treatment options. The main symptoms are headaches, nausea, loss of coordination, and behavioral changes, which generally necessitates early diagnosis and a comprehensive approach to the treatment of this disease.

History of the disease and interesting historical facts

Medulloblastoma was first described in dermatological and neurosurgical literature in the early 20th century, with subsequent studies clarifying its morphology and clinical manifestations. In 1925, Professor N. L. Kustov proposed a classification of cerebellar tumors that included medulloblastoma. Since then, researchers have improved their understanding of the pathogenesis and tumor biology of medulloblastoma, leading to advances in diagnostic and treatment methods. One of the major advances in treatment has been the introduction of adjuvant chemotherapy and modern radiation therapy, which has significantly increased the survival rate of patients with medulloblastoma.

Epidemiology

According to statistics, medulloblastoma occurs in 3-5 cases per 1 million people per year. The highest incidence is in the age group of 3 to 8 years, and approximately 70% cases occur in boys. The incidence in children may vary depending on the region and ethnicity. According to various epidemiological studies, there is a significant difference in the incidence of medulloblastoma among different racial groups, which may be due to genetic and environmental factors. In addition, studies show that medulloblastoma is more common in patients with hereditary syndromes, such as Li-Fraumeni syndrome and Neurofibromatosis type 1 syndrome.

Genetic predisposition to this disease

Studies have shown that medulloblastoma has both hereditary and spontaneous genetic mutations. Important genes involved in the development of medulloblastoma include TP53, CTNNB1, MYC, and others. In patients with hereditary syndromes such as Li-Fraumeni syndrome, mutations in the TP53 gene significantly increase the risk of developing medulloblastoma. Recent studies are actively exploring the molecular mechanisms that lead to the activation of fixed signaling pathways such as Wnt, SHH, and Notch, which may also contribute to the pathogenesis of medulloblastoma. These discoveries open up new prospects for the creation of targeted therapies.

Risk factors for the development of this disease

There are several risk factors that may increase your chance of developing medulloblastoma. These include:

• Genetic predisposition: presence of hereditary diseases such as Li-Fraumeni syndrome or Neurofibromatosis syndrome.
• Environmental factors: exposure to toxic substances, possibly such as pesticides or industrial chemicals.
• Age: The highest risk is seen in children aged 3 to 8 years.
• Gender: According to research, boys are more common than girls.

Each of these factors may interact with others, making it difficult to determine the exact cause of medulloblastoma.

Diagnosis of this disease

The main symptoms of medulloblastoma include:

• Headaches, especially in the morning.
• Nausea and vomiting.
• Impaired coordination of movements and balance.
• Changes in behavior and academic activity.

To diagnose the disease, the following laboratory and radiological studies are carried out:

• Complete blood count and biochemical tests to rule out infectious and inflammatory diseases.
• Magnetic resonance imaging (MRI) to visualize the tumor and assess its extent.
• Computed tomography (CT) scan to provide more detailed images of the head and neck.
• Pathological examination of tissue after surgery to confirm the diagnosis.

It is important to consider the differential diagnosis with other brain tumors and neurological disorders.

Treatment

Treatment of medulloblastoma requires a multidisciplinary approach and may include several methods:

• Surgical intervention to remove the tumor, which is the first stage of treatment and is necessary to reduce the volume of the tumor mass.
• Radiation therapy, which is used to kill any remaining cancer cells and prevent recurrence.
• Chemotherapy typically involves a full course of treatment after surgery and radiation therapy, using combination regimens such as BEA (vincristine, etoposide, cyclophosphamide) and other drugs.

More recently, research has begun into new targeted and immunotherapies that may improve treatment outcomes.

List of medications used to treat this disease

Some of the main drugs used in the treatment of medulloblastoma include:

• Vincristine
• Cyclophosphamide
• etoposide
• Carmustine
• Lomustine
• Methotrexate
• Tegozir (also registered as immunotherapy)

Each of these agents is used depending on the molecular subtype of medulloblastoma and the presence of concomitant diseases.

Disease monitoring

Post-treatment monitoring includes regular controlled examinations:

• MRI to assess the possibility of recurrence.
• Complete blood counts to detect the effects of chemotherapy.

The prognosis for patients with medulloblastoma varies depending on the tumor subtype and the presence of metastases. Complications may include neuropsychiatric disorders, endocrine disorders, and secondary tumors.

Age-related features of the disease

Medulloblastoma is most often diagnosed in children, but in rare cases it can occur in adults. In children, the disease is more aggressive and is more likely to metastasize. In adults, the clinical picture is often less pronounced, which can make diagnosis in the early stages difficult. Treatment in this age group may require a more individualized approach, taking into account the overall health of the patients.

Questions and Answers

• What is medulloblastoma?
  Medulloblastoma is a highly aggressive tumor of nervous tissue, most often arising in the cerebellum in children and having a high risk of metastasis.
• What are the main symptoms of medulloblastoma?
  The main symptoms include headaches, nausea, vomiting, loss of coordination, and changes in behavior. These symptoms may be signs of pressure on the brain.
• How is medulloblastoma treated?
  Treatment includes surgical removal of the tumor, radiation therapy and chemotherapy. The treatment program is determined individually depending on many factors.
• What are the risk factors for medulloblastoma?
  Risk factors include hereditary syndromes, environmental factors, age and gender.
• What is the prognosis for medulloblastoma?
  The prognosis depends on the stage of the disease, the tumor subtype and the presence of metastases, as well as the success of treatment. Without treatment, five-year survival is about 30%, with adequate treatment it is significantly higher.